227 related articles for article (PubMed ID: 18684975)
1. Molecular mechanisms of TGF beta receptor-triggered signaling cascades rapidly induced by the calcineurin inhibitors cyclosporin A and FK506.
Akool el-S; Doller A; Babelova A; Tsalastra W; Moreth K; Schaefer L; Pfeilschifter J; Eberhardt W
J Immunol; 2008 Aug; 181(4):2831-45. PubMed ID: 18684975
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathway.
Akool el-S; Doller A; Müller R; Gutwein P; Xin C; Huwiler A; Pfeilschifter J; Eberhardt W
J Biol Chem; 2005 Nov; 280(47):39403-16. PubMed ID: 16183640
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR.
Osman B; Doller A; Akool el-S; Holdener M; Hintermann E; Pfeilschifter J; Eberhardt W
Cell Signal; 2009 Dec; 21(12):1806-17. PubMed ID: 19666112
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy.
Li J; Campanale NV; Liang RJ; Deane JA; Bertram JF; Ricardo SD
Am J Pathol; 2006 Nov; 169(5):1527-40. PubMed ID: 17071578
[TBL] [Abstract][Full Text] [Related]
5. FK506 inhibits the mice glomerular mesangial cells proliferation by affecting the transforming growth factor-β and Smads signal pathways.
Qi R; Li W; Yu S
Ren Fail; 2014 May; 36(4):589-92. PubMed ID: 24512120
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporin A and tacrolimus induce renal Erk1/2 pathway via ROS-induced and metalloproteinase-dependent EGF-receptor signaling.
Akool el-S; Gauer S; Osman B; Doller A; Schulz S; Geiger H; Pfeilschifter J; Eberhardt W
Biochem Pharmacol; 2012 Jan; 83(2):286-95. PubMed ID: 22100870
[TBL] [Abstract][Full Text] [Related]
7. Activation of renal profibrotic TGFβ controlled signaling cascades by calcineurin and mTOR inhibitors.
Eberhardt W; Nasrullah U; Pfeilschifter J
Cell Signal; 2018 Dec; 52():1-11. PubMed ID: 30145216
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus induces fibroblast-to-myofibroblast transition via a TGF-β-dependent mechanism to contribute to renal fibrosis.
Ume AC; Wenegieme TY; Shelby JN; Paul-Onyia CDB; Waite AMJ; Kamau JK; Adams DN; Susuki K; Bennett ES; Ren H; Williams CR
Am J Physiol Renal Physiol; 2023 May; 324(5):F433-F445. PubMed ID: 36927118
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
Laping NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA
Mol Pharmacol; 2002 Jul; 62(1):58-64. PubMed ID: 12065755
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.
Kapoun AM; Gaspar NJ; Wang Y; Damm D; Liu YW; O'young G; Quon D; Lam A; Munson K; Tran TT; Ma JY; Murphy A; Dugar S; Chakravarty S; Protter AA; Wen FQ; Liu X; Rennard SI; Higgins LS
Mol Pharmacol; 2006 Aug; 70(2):518-31. PubMed ID: 16707625
[TBL] [Abstract][Full Text] [Related]
12. Induction of renal fibrotic genes by TGF-β1 requires EGFR activation, p53 and reactive oxygen species.
Samarakoon R; Dobberfuhl AD; Cooley C; Overstreet JM; Patel S; Goldschmeding R; Meldrum KK; Higgins PJ
Cell Signal; 2013 Nov; 25(11):2198-209. PubMed ID: 23872073
[TBL] [Abstract][Full Text] [Related]
13. Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation.
Hasan M; Neumann B; Haupeltshofer S; Stahlke S; Fantini MC; Angstwurm K; Bogdahn U; Kleiter I
Immunol Cell Biol; 2015 Aug; 93(7):662-72. PubMed ID: 25823994
[TBL] [Abstract][Full Text] [Related]
14. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
Inman GJ; Nicolás FJ; Callahan JF; Harling JD; Gaster LM; Reith AD; Laping NJ; Hill CS
Mol Pharmacol; 2002 Jul; 62(1):65-74. PubMed ID: 12065756
[TBL] [Abstract][Full Text] [Related]
15. Requirement of a dynein light chain in TGFbeta/Smad3 signaling.
Jin Q; Gao G; Mulder KM
J Cell Physiol; 2009 Dec; 221(3):707-15. PubMed ID: 19711352
[TBL] [Abstract][Full Text] [Related]
16. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism.
Rodríguez-Vita J; Sánchez-López E; Esteban V; Rupérez M; Egido J; Ruiz-Ortega M
Circulation; 2005 May; 111(19):2509-17. PubMed ID: 15883213
[TBL] [Abstract][Full Text] [Related]
18. Identification of TGF-β receptor-1 as a key regulator of carbon nanotube-induced fibrogenesis.
Mishra A; Stueckle TA; Mercer RR; Derk R; Rojanasakul Y; Castranova V; Wang L
Am J Physiol Lung Cell Mol Physiol; 2015 Oct; 309(8):L821-33. PubMed ID: 26472812
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-β1 induces type II collagen and aggrecan expression via activation of extracellular signal-regulated kinase 1/2 and Smad2/3 signaling pathways.
Zhu Y; Tao H; Jin C; Liu Y; Lu X; Hu X; Wang X
Mol Med Rep; 2015 Oct; 12(4):5573-9. PubMed ID: 26165845
[TBL] [Abstract][Full Text] [Related]
20. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
